Tempest Therapeutics financials
$0.8103−2.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M | -$28.3M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-6.33 | $-19.50 | $-24.83 | $-40.17 | $-97.11 |
| EBITDA | -$26.3M | -$41.6M | -$28.8M | -$34.0M | -$26.6M |
| Operating cash flow | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M |
| Diluted shares | 4.1M | 2.1M | 1.2M | 0.9M | 0.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.7M | $30.3M | $39.2M | $31.2M | $51.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $6.4M | $10.5M | $10.4M | $15.1M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M |
| Shareholders' equity | $6.7M | $19.1M | $26.8M | $18.1M | $36.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology